Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series LLC LTD Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series LLC LTD : World’s leading Event Organizer


25th World Congress on Cancer Science and Therapy

Baltimore, USA

Erin Awad Rezk Sharkawy

Cairo University, Egypt

Title: Serum SAA2 protein as a diagnostic biomarker for egyptian Hepatocellular Carcinoma patients associated with HCV Infection


Biography: Erin Awad Rezk Sharkawy


Hepatitis C virus (HCV) is a single stranded RNA virus, of the Flaviviridae family. It is the main cause of chronic HCV diseases like fibrosis, cirrhosis, HCC and end stage liver disease. Worldwide, about 71 millions of individuals have HCC resulting from HCV chronic infection with about 790 thousands annual deaths. A major cause of high mortality rate due to HCC is the lack of early diagnostic resources. There is a great need for a sensitive, specific and non-invasive diagnostic marker to detect HCC in the earlier stages. We studied four protein markers in serum (SAA2, KNG1, PON1 and GAL3) that were significantly elevated in HCV-related HCC patients in previous study in our lab using C-MS/MS screening analysis and separated by SDS-PAGE gel electrophoresis. Estimation of protein concentrations were done in 52 patients infected with HCV-free HCC, 51 with HCV-related HCC in addition to 40 healthy participants as a control group. Analyses of protein concentrations were performed using sandwich ELISA technique. From the studied biomarkers, SAA2 provided the highest diagnostic accuracy (AUC=0.925) for HCC patients at (p<0.001). Morever, the diagnostic accuracy increased slightly when we used the panel of SAA2 with AFP, together with AUC=0.946, for HCC patients. SAA2 may have a considerable use in early detection of HCC in both normal population and high-risk patients.